Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
26.27
-0.16 (-0.61%)
At close: Oct 7, 2025, 4:00 PM EDT
26.28
+0.01 (0.03%)
After-hours: Oct 7, 2025, 7:59 PM EDT
Revenue
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|
Jun '25 Jun 29, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
---|
| 29.21B | 30.14B | | | | |
| 17.09B | 16.65B | | | | |
| 16.25B | 15.61B | | | | |
Global Pharmaceuticals Business (Biopharma) Revenue | 62.55B | 62.40B | | | | |
Business Innovation (Pfizer CentreOne) Revenue | 1.20B | 1.15B | | | | |
| 86.00M | 81.00M | | | | |
| 63.83B | 63.63B | | | | |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|
Jun '25 Jun 29, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
---|
| 38.55B | 38.69B | | | | |
Developed Markets Revenue | 16.27B | 16.06B | | | | |
Emerging Markets Revenue (Post-FY2023 Reporting) | 9.01B | 8.88B | | | | |
| - | - | | | | |
| 63.83B | 63.63B | | | | |
Revenue by Geography 2
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|
Jun '25 Jun 29, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
---|
| 38.55B | 38.69B | | | | |
| 63.83B | 63.63B | | | | |
Revenue by Geography 3
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|
Jun '25 Jun 29, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
---|
| 38.55B | 38.69B | | | | |
| - | - | | | | |
Developed Rest of World Revenue | - | - | | | | |
| - | - | | | | |
| 25.28B | 24.94B | | | | |
| 63.83B | 63.63B | | | | |
EBT
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|
Jun '25 Jun 29, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
---|
Global Pharmaceuticals Business (Biopharma) Earnings | 28.65B | 28.14B | | | | |
Other Business Activities Earnings | -6.61B | -7.38B | | | | |
Key Performance Indicators
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|
Jun '25 Jun 29, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
---|
Comirnaty Direct Sales and Alliance Revenue | 5.75B | 5.35B | | | | |
Eliquis Alliance Revenue and Direct Sales | 7.38B | 7.37B | | | | |
| - | - | | | | |
| 4.35B | 5.72B | | | | |
| 6.40B | 6.41B | | | | |
Nurtec ODT/Vydura Revenue | 1.34B | 1.26B | | | | |
| 828.00M | 755.00M | | | | |
| 6.09B | 5.45B | | | | |
| 1.12B | 1.17B | | | | |
| 4.21B | 4.37B | | | | |
| - | - | | | | |
Internal Medicine Revenue | - | - | | | | |
| - | - | | | | |
Inflammation & Immunology Revenue | - | - | | | | |
| - | - | | | | |
Updated Aug 5, 2025. Data Source:
Fiscal.ai.